Basilea Pharmaceutica AG BPMUF
Set alert
At close · Oct 30
- YTD
- +22.37%
- 1 year
- +29.06%
- Open
- 77.40
- Prev close
- 76.25
- Mkt cap
- 959.30M
- Vol
- 100
- Avg vol
- 6
- EPS
- 5.05
- P/E
- 15.33
More statistics
- Low
- 77.40
- High
- 77.40
News
2 months ago seekingalpha.com
Basilea Pharmaceutica AG (BPMUF) Q2 2026 Earnings Call Transcript
Basilea Pharmaceutica AG (BPMUF) Q2 2026 Earnings Call Transcript
2 months ago defenseworld.net
Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update
Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) was the target of a large growth in short interest in July. As of July 31st, there was short interest totaling 474 shares, a growth of…
5 months ago globenewswire.com
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 28, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the…
6 months ago globenewswire.com
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
Allschwil, Switzerland, April 15, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial…
6 months ago globenewswire.com
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor)…
7 months ago globenewswire.com
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial…
8 months ago globenewswire.com
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to…
8 months ago seekingalpha.com
Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript
Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript
8 months ago globenewswire.com
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
15% royalty income increase 11% total revenue increase Tripled net cash position Phase 3 program with fosmanogepix progressing as planned Financial guidance FY 2026: Double-digit increase in total…
8 months ago globenewswire.com
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe…
9 months ago globenewswire.com
Basilea provides portfolio update and outlook
Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal…
9 months ago prnewswire.com
Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections
UNION, N.J., Jan. 7, 2026 /PRNewswire/ -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement…
10 months ago businesswire.com
Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI
BOSTON--(BUSINESS WIRE)--Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage…
10 months ago globenewswire.com
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe…
12 months ago globenewswire.com
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to…
1 year ago globenewswire.com
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million
1 year ago globenewswire.com
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to…
1 year ago seekingalpha.com
Basilea Pharmaceutica AG (BPMUF) Q2 2025 Earnings Conference Call Transcript
Basilea Pharmaceutica AG (OTC:BPMUF) Q2 2025 Earnings Conference Call August 19, 2025 10:00 AM ET Company Participants Adesh Kaul - Chief Financial Officer David Veitch - Chief Executive Officer Marc…
1 year ago globenewswire.com
Basilea on track with strong 2025 half-year results
Cresemba ® and Zevtera ® -related revenues rise by 24% to CHF 90.5 million Total revenue grows significantly by 36% to CHF 104.0 million Operating profit surges by 160% to CHF 24.0 million Operating…
1 year ago globenewswire.com
Assessment of the 14-Alpha Demethylase Inhibitors Pipeline Landscape 2025, Featuring Insights Into Oteseconazole (Mycovia Pharmaceuticals) and Isavuconazonium (Basilea Pharmaceutica)
Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "14-alpha Demethylase Inhibitors - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides…